Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange
Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...
Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal
US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered...
GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324
UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...
Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC
US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with...
Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO
Cloudbreak Pharma Inc., a Cayman Island-registered ophthalmology biotech company, has filed for an initial public...
COUR Pharmaceutical Enters Licensing Agreement with Genentech for Autoimmune Disease Treatment
US-based COUR Pharmaceutical has announced a strategic collaboration and licensing agreement with Genentech, a member...
Guangzhou Virotech’s Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA
Guangzhou Virotech Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has announced receiving tacit clinical approval...
Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager
France-based Ipsen (OTCMKTS: IPSEY) has announced a significant global licensing agreement with compatriot firm Biomunex...
OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody
US-based OncoC4, Inc. has announced that it has received clinical clearance from the US Food...
Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from...
Sacituzumab Tirumotecan Earns FDA Breakthrough Therapy Designation for EGFR Mutated NSCLC
Sacituzumab tirumotecan (SKB264/MK-2870), a TROP2-targeted antibody drug conjugate (ADC) co-developed by Merck, Sharp & Dohme...
Merck’s Recarbrio Approved by NMPA for Hospital-Acquired Infections and Complicated UTIs
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has announced that it...
Abbisko Therapeutics Gets FDA Green Light for Phase I Study of ABSK131 Inhibitor
Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations
The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and...
InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...
Shanghai Henlius Biotech’s Serplulimab Approved for First-Line nsNSCLC Treatment in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced that it has received marketing approval from...
Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521), through its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd.,...
HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer
Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Acotec Scientific’s AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...